4971 results for "Psychedelics"
A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
Journal of Psychoactive Drugs – June 12, 2020
Summary
Psychedelic-assisted therapy shows remarkable promise, with nine randomized controlled clinical trials revealing an impressive effect size of 1.21, exceeding typical psychopharmacological interventions. These clinical trials, a resurgence in drug studies for medicine and psychiatry, examined hallucinogens like psilocybin, LSD, and ayahuasca (containing N,N-dimethyltryptamine and harmala monoamine oxidase inhibitor alkaloids). Administered alongside a placebo, these psychedelics demonstrated efficacy across four conditions, including anxiety and unipolar depression. This field of clinical psychology explores how these compounds influence behavior, signaling a new era in mental health treatment.
Abstract
After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted ther...
Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change
Bulletin of Taras Shevchenko National University of Kyiv Psychology – January 01, 2023
Summary
Psychedelic-assisted therapy significantly boosts subjective well-being. For 33 individuals, combining meditation with psychedelic therapy notably reduced anxiety and improved self-awareness. This offers a powerful alternative for mental health challenges like depression, where traditional clinical psychology, often involving a psychotherapist, or psychiatry may fall short. Such drug studies provide hope for populations facing acute distress, enhancing psychological well-being. These novel approaches, leveraging specific alkaloids, represent a new frontier in mental health treatment.
Abstract
Background. As a result of the military attack in Ukraine, both the military and civilian population are facing mental health disorders such as pos...
Psychedelic-like Activity of Norpsilocin Analogues
ACS Chemical Neuroscience – January 08, 2024
Summary
Norpsilocin, a primary metabolite of psychedelic mushrooms, typically lacks psychedelic effects *in vivo*, despite being a potent serotonin 2A receptor agonist *in vitro*. Its poor brain permeability was hypothesized. Through chemical synthesis and drug studies, eight norpsilocin derivatives were created. Pharmacology studies revealed that simply extending norpsilocin's *N*-methyl group to an *N*-ethyl group restored psilocin-like psychedelic activity *in vivo* at a dose of 1.4 mg/kg. Other derivatives also acted as agonists, inducing 26-77 head-twitch events. This biochemical analysis highlights key structural requirements for CNS-mediated psychedelic effects.
Abstract
Primary metabolites of mushroom tryptamines, psilocybin and baeocystin (i.e., psilocin and norpsilocin), exhibit potent agonist activity at the ser...
Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
Despite widespread use of psychedelics, only 28 drug-related deaths were linked to these substances across England, Wales, and Northern Ireland over 25 years. While each death is tragic, this remarkably low number supports psychedelics' relative safety profile. Most cases involved multiple substances, with LSD and psilocybin being most common. Adverse effects were typically connected to unsafe physical environments or toxicity from mixing drugs.
Abstract
Psychedelic drugs are increasingly visible in society once more, but their risks and adverse effects have received less attention than perhaps they...
Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment
Medical Science Monitor – June 30, 2025
Summary
Psychedelics offer compelling potential for mental health, addressing severe conditions like depression and PTSD. These substances, including those from chemical synthesis and alkaloids, are explored in Psychiatry and Psychology. A psychotherapist might integrate them into Medicine, yet current Drug Studies, often found in MEDLINE, confirm psychedelic-assisted therapy remains experimental due to a scarcity of large-scale trials. While unique mechanisms, such as those related to Nicotinic Acetylcholine Receptors, are under study, robust evidence is crucial for patients needing intensive care medicine-level attention for complex mental health challenges.
Abstract
Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-rev...
Treatment-Resistant Depression: A Comprehensive Insight of Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Psychedelic-Assisted Psychotherapy
Annals of Punjab Medical College – December 31, 2024
Summary
New hope emerges for treatment-resistant depression, with effective alternative therapies showing promise. A systematic review of 80 studies, comprising 55 clinical trials, 10 meta-analyses, and 10 systematic reviews, highlights significant clinical improvements from ketamine infusion therapy, transcranial magnetic stimulation (TMS), and psychedelic-assisted psychotherapy. Ketamine and psychedelic-assisted psychotherapy, in particular, offer compelling advancements, providing substantial relief for patients who haven't responded to traditional treatments.
Abstract
Background: The phenomenon of treatment-resistant depression (TRD) remains a problem in the sphere of mental health treatment since the majority of...
Phenomenology of Psychedelic Experiences and Psychedelic-Associated Distressing Effects: Quantifying Subjective Experiences.
Current topics in behavioral neurosciences – December 31, 2024
Summary
No Summary
Abstract
The range of phenomena that can be induced by psychedelic substances is broad and variable, including effects on perception, cognition, and emotion...
Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution.
Journal of psychoactive drugs – February 13, 2025
Summary
Personal mindset plays a bigger role than physical environment in shaping profound psychedelic experiences. A study of 862 users found that those seeking spiritual growth or healing reported more intense ego dissolution than those driven by curiosity. This suggests internal factors matter more than external setting in naturalistic psychedelic use.
Abstract
Psychedelics have the potential to induce profound alterations in cognition, emotionality, and sensory perception. The quality and intensity of the...
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Frontiers in Psychology – June 10, 2022
Summary
Psychedelic-assisted psychotherapy shows compelling outcomes, yet some patients relapse. A review using **MEDLINE**, **Scopus**, and **PsycINFO** examined **clinical psychology** models for **Psychedelics and Drug Studies**. These **psychological intervention** approaches, delivered by a **psychotherapist**, highlight how individual **set** and environmental **context** influence efficacy. Such **interventions (counseling)** demonstrate the **moderation** of therapeutic factors on outcomes, considering the **chemical synthesis and alkaloids** involved and their **neurotransmitter receptor influence on behavior**. This **Psychology** review maps current practices, emphasizing therapeutic stance for improved patient care.
Abstract
Modern clinical research on psychedelics is generating interesting outcomes in a wide array of clinical conditions when psychedelic-assisted psycho...
Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychotic Symptoms
Research Square (Research Square) – January 25, 2022
Summary
Expert opinion suggests psychedelic-assisted psychotherapy needn't be contraindicated for all with psychotic symptoms. 12 psychiatry and clinical psychology experts indicate highly supportive therapy, using synthesized compounds like psilocybin (an alkaloid), could significantly improve quality of life. Current Psychedelics and Drug Studies often exclude these cases, but a psychotherapist's strong therapeutic alliance and trauma understanding are crucial. This challenges psychology on how these compounds influence behavior, warranting re-evaluation.
Abstract
Abstract Background Currently, personal or familial histories of psychotic symptoms are exclusionary criteria for most psychedelic clinical trials,...
Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice.
Psychopharmacology – May 17, 2025
Summary
Female mice show stronger responses to classic psychedelics like LSD and psilocybin, revealing important sex-based differences in how these compounds affect the brain. Scientists tracked the distinctive head twitch response - a reliable marker of psychedelic activity linked to 5-HT2A receptor activation. While both male and female mice reacted similarly to low doses, females displayed notably more intense responses at higher doses across all tested psychedelics.
Abstract
The head twitch response (HTR) is a spontaneously occurring behavior in mice that is increased in frequency by serotonergic psychedelics. The mouse...
Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.
Cureus – April 01, 2025
Summary
Breakthrough findings show 70% of patients with hard-to-treat depression improved significantly with psychedelic-assisted therapy. Analysis of recent trials reveals both ketamine and psilocybin treatments led to rapid antidepressant response, with benefits lasting months. Depression scales showed marked improvement in mood, while cognitive effects remained stable or enhanced. This comprehensive review confirms these treatments are safe and effective for treatment-resistant depression.
Abstract
This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-r...
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases
Cochrane Database of Systematic Reviews – September 11, 2024
Summary
Psychedelic-assisted therapy offers hope for profound relief from severe anxiety, depression, and existential distress, including death anxiety, in those facing life-threatening illness. These compounds, products of chemical synthesis and alkaloids, are being investigated in psychology and psychiatry for their impact on brain disorders. While current clinical psychology trials show them well-tolerated with no serious adverse events, the evidence certainty is low. Psychotherapists are keenly observing these developments in medicine and drug studies, as they could revolutionize mental health treatment.
Abstract
Implications for practice Psychedelic-assisted therapy with classical psychedelics (psilocybin, LSD) may be effective for treating anxiety, depress...
Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy.
Frontiers in psychiatry – January 01, 2025
Summary
During psychedelic-assisted psychotherapy, music transforms from simple audio into a multisensory, personalized experience. Research shows that patients receiving psilocybin treatment in palliative care settings experienced music as an active collaborator in their healing journey, unlike those given placebo. The music became a therapeutic tool, creating deeply meaningful experiences that enhanced end-of-life care.
Abstract
Music has been identified as a central feature of psychedelic-assisted psychotherapy (PAP) and has hitherto been understood to amplify the psychede...
Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
Frontiers in Psychology – March 04, 2022
Summary
Psychedelics, like the natural compound psilocybin, show profound promise in psychology for treating anxiety and influencing consciousness. These hallucinogens require careful psychotherapist guidance and a supportive mindset. Virtual reality (VR) could significantly enhance this, aiding relaxation, promoting mindfulness, and complementing practices like meditation. While VR’s potential to deepen these experiences is compelling, its synergy with psychedelics demands rigorous evaluation in drug studies to understand its full impact on behavior.
Abstract
Psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymetha...
Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’
Deleuze and Guattari Studies – October 27, 2023
Summary
Psychedelic therapy, especially with psilocybin, often restricts the unconscious mind's vast potential by overemphasizing mystical experience as the singular therapeutic goal, a trend prevalent over the past fifteen years. Drawing on Deleuze and Guattari's critique of psychoanalysis, a new approach for psychotherapists emerges. Instead of reducing psychic visions to a quantifiable ideal, therapy should embrace a "desiring-machine" model. This perspective, integrating diverse academic research themes in Psychedelics and Drug Studies, fosters a unique, less constrained exploration of individual processes, moving beyond predetermined aesthetic or spiritual outcomes.
Abstract
This paper argues that practitioners of psychedelic-assisted therapy could learn a great deal from Deleuze and Guattari’s critique of psychoanalysi...
Exploring Jordanian Physicians' and Medical Students' Perspectives on Ketamine and Psychedelic-Assisted Therapies: An Insight from the Middle East.
Journal of psychoactive drugs – July 06, 2025
Summary
In Jordan, many physicians and medical students surprisingly show limited familiarity with psychedelic-assisted therapies. A survey explored their attitudes and perceptions towards these emerging mental health treatments, including ketamine. While most respondents were unfamiliar with psychedelics, findings reveal varied perceptions: some oppose, but a significant portion are cautious or supportive. Demographics like age and gender influenced these attitudes. This highlights a clear opportunity for education to enhance understanding of these promising new approaches.
Abstract
Psychedelic-assisted therapies and ketamine are two modalities gaining attention in psychiatry for treating conditions such as depression, PTSD, an...
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Frontiers in Psychiatry – April 05, 2023
Summary
A critical insight reveals *Psychedelics and Drug Studies* often misinterpret "mystical experiences" from compounds influencing *Neurotransmitter Receptor Influence on Behavior*. While *Psychology* notes positive mental health outcomes, a rigorous *Epistemology* shows current *mysticism* definitions are historically biased, overlooking diverse cultural contexts. This impacts how *Psychotherapists* apply insights. A *psychoanalytic* lens, alongside understanding *chemical synthesis and alkaloids*, is crucial for nuanced frameworks. Addressing these definitional flaws is an *engineering ethics* challenge for designing rigorous, unbiased research protocols, ensuring true understanding.
Abstract
Contemporary research on serotonergic psychedelic compounds has been rife with references to so-called ‘mystical’ subjective effects. Several psych...
Psychedelic-assisted psychotherapy: The need to monitor adverse events.
Journal of psychopharmacology (Oxford, England) – May 21, 2025
Summary
While psychedelic-assisted therapy shows remarkable potential for mental health treatment, proper monitoring of adverse events remains crucial for patient safety. Medical professionals are developing comprehensive protocols to track physical and behavioral responses during these treatments. The approach combines careful vital sign monitoring with detailed patient experience reporting, ensuring both effectiveness and safety. Special attention is given to individual factors like gender differences and pre-existing conditions.
Abstract
The therapeutic use of psychedelics for mental health issues holds considerable promise. However, systematic assessment of adverse events associate...
Radiation therapy patients' interest in psychedelic-assisted therapy: results of a survey.
Radiation oncology (London, England) – July 21, 2025
Summary
No Summary
Abstract
Comorbid mental health symptoms impact 30-40% of cancer patients, significantly compromising treatment adherence and increasing mortality rates. Am...
Memory, trauma, and self: Remembering and recovering from sexual abuse in psychedelic-assisted therapy
Journal of Psychedelic Studies – October 09, 2024
Summary
Psilocybin offers compelling potential for treating Post-Traumatic Stress Disorder from sexual abuse, a condition often resistant to conventional psychotherapy techniques. Findings from *Natural Compound Pharmacology Studies* on two individuals in a weeklong psychedelic retreat revealed profound healing. The *psychology* benefits extended beyond typical drug effects; psilocybin facilitated retrieving repressed traumatic memories, enabling conscious awareness and reconciliation. This *clinical psychology* work suggests that re-narrating one's identity is crucial. A *psychotherapist* could consider these *psychedelics and drug studies* for future trauma applications.
Abstract
Abstract Background and Aims This article examines the therapeutic potential of psilocybin in addressing Post-Traumatic Stress Disorder as the resu...
Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2025
Summary
Rural communities disproportionately bear health burdens, highlighting the critical need for equitable access to emerging treatments. As psychedelic-assisted therapy nears approval, ensuring its availability in rural settings is crucial for rural medicine. This perspective explores barriers and proposes solutions: integrating PAT into rural psychiatry training, utilizing teletherapy for remote care, and creating incentives for providers. Creative strategies can ensure rural populations benefit from these promising therapies.
Abstract
With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedio...
Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
Underground psychedelic facilitators report that personal healing experiences with substances like psilocybin, LSD, and MDMA drive their commitment to helping others. Their insights reveal consistent yet adaptable therapeutic approaches, emphasizing the client's innate healing capacity. While supporting broader access to psychedelic medicine, these practitioners express concern about over-standardization limiting the personalized care that makes their work effective.
Abstract
There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, pu...
Mystical Experience with Cancer Patients: Insights from Psychedelic-Assisted Psychotherapy and Guided Imagery
Global Journal of Medical Research – July 31, 2021
Summary
Profound "mystical experiences" from psilocybin-assisted psychotherapy directly correlate with alleviating cancer-related distress. This article explores whether combining a psychotherapist's guided imagery, where patients create a mental image, with these powerful psychedelics could not only reduce psychological distress but also potentially shrink physiological tumors. It examines modalities, mysticism in psychology and patient experience, and anecdotal outcomes from natural compound pharmacology studies, bridging medicine, trance, and drug studies.
Abstract
Background: In controlled, clinical studies of the impact of psilocybin on patients with life-threatening cancers, Johns Hopkins and NYU researcher...
Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
Advances in Research – January 30, 2023
Summary
Over 700 million individuals globally suffer from mental illness, highlighting the urgent need for new medicine. Psychedelic-assisted psychotherapy offers astounding, fast results where traditional treatments often fall short. Supervised sessions by a clinical psychology psychotherapist or psychiatrist, integrating compounds like psilocybin, MDMA, and lysergic acid diethylamide, are transforming mental health care. This emerging field of psychiatry and psychology is exploring these powerful hallucinogens for conditions like anxiety, representing a new promise in drug studies.
Abstract
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted w...
Neurobiological Correlates of Psychedelic Experiences and Psychedelic-Associated Adverse Effects.
Current topics in behavioral neurosciences – July 31, 2024
Summary
No Summary
Abstract
This chapter offers a comprehensive overview of our current understanding of the neural mechanisms underlying the effects of psychedelic drugs, wit...
Ethische Aspekte der Therapie mit Psychedelika
Die Psychotherapie – February 09, 2024
Summary
As a growing number of psychedelic-assisted therapy studies emerge, profound ethical questions demand attention. Patients undergoing treatment with these powerful alkaloids experience heightened suggestibility and temporary ego dissolution, fundamentally impacting worldviews and deep convictions. This necessitates immense therapist responsibility and rigorous informed consent, addressing the philosophical dimensions of such experiences. Integrating these potent compounds into medicine, an area of active drug studies, requires a societal discussion on their unique ethical landscape.
Abstract
Zusammenfassung Hintergrund In den letzten Jahren wurde die klinische Forschung zu Psychedelika-gestützter Therapie psychischer Störungen wieder au...
Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism
Magna Scientia Advanced Research and Reviews – June 28, 2025
Summary
Trauma and substance use are profoundly underdiagnosed and undertreated in individuals with Level 1 Autism. While promising psychedelic-assisted therapies (e.g., psilocybin, MDMA, ketamine) address PTSD, and digital mental health interventions improve access, their intersection with autistic needs remains critically underexplored. This psychology review proposes a neurodevelopmentally sensitive, hybrid model. It integrates digital mental health tools with psychedelic psychological interventions to enhance mental health and trauma healing for autistic populations, addressing critical gaps in clinical psychology and psychiatry.
Abstract
Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Leve...
Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care.
Neuropharmacology – September 15, 2022
Summary
Many facing serious illnesses grapple with profound Anxiety, Depression, and Demoralization syndrome, where current Palliative care treatments often fall short, especially for Existential distress. A compelling review highlights Psychedelics, when combined with psychotherapy, as a promising new approach. By examining efficacy data from past research, the analysis suggests these therapies could significantly alleviate these complex psychiatric and existential burdens, forging a new path for patient well-being.
Abstract
Psychiatric and existential distress commonly occur in advanced cancer and other serious, life-threatening or end-of-life medical illnesses and are...
An Overview of Psychedelic-Assisted Therapy
EMBARK Psychedelic Therapy for Depression – April 23, 2024
Summary
A novel therapeutic model, EMBARK, is revolutionizing mental health support. It proposes a new, adaptable framework for psychedelic-assisted therapy. This approach emphasizes structured phases: preparation, medicine administration, and crucial integration, supported by therapeutic guidance. Piloted in trials, EMBARK offers comprehensive, flexible mental health treatment, aiming to provide broad therapeutic support.
Abstract
AbstractChapter 1 introduces the concept of psychedelic-assisted therapy (PAT) and the EMBARK psychedelic therapy model, a new approach to PAT and ...
Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment
The journal of desk research review and analysis. – December 16, 2025
Summary
Psychedelic-assisted therapy (PAT) shows remarkable potential in treating mental health disorders, with studies indicating a 60-70% reduction in depression symptoms among participants. Recent clinical trials from 2020 to 2024 involved diverse sample sizes, revealing significant benefits for conditions like PTSD and substance use disorders. Emerging evidence emphasizes the importance of addressing ethical issues and exploring underrepresented groups, such as older adults. This synthesis highlights the need for continued investigation into PAT's mechanisms and regulatory frameworks, paving the way for future advancements in psychiatry and psychology.
Abstract
Psychedelic-assisted therapy (PAT) has emerged as a promising and innovative approach to treating a range of mental health disorders, including dep...
How to make psychedelic-assisted therapy safer
Cambridge Quarterly of Healthcare Ethics – September 27, 2024
Summary
While promising, psychedelic therapy can temporarily diminish a patient's autonomy. To enhance safety, various measures were examined. Findings show preparatory sessions and trained oversight are valuable. Critically, including a trusted close person in the session is a highly effective and feasible approach to protect patients and foster a positive therapeutic experience.
Abstract
Classic serotonergic psychedelics are experiencing a clinical revival, which has also revived ethical debates about psychedelic-assisted therapy. A...
Further education in psychedelic-assisted therapy - experiences from Switzerland.
BMC medical education – March 05, 2025
Summary
Switzerland leads the way in therapist training for psychedelic-assisted therapy, offering a unique three-year program that combines clinical expertise with personal psychedelic experience. Under limited medical use policies, Swiss practitioners can legally use MDMA, psilocybin, and LSD to treat mental health conditions. The program emphasizes hands-on experience, ethical practice, and therapeutic relationships.
Abstract
The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anx...
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Psychopharmacology – August 01, 2024
Summary
While psychedelic medicines like psilocybin show promise in mental health treatment, the therapy component of psychedelic-assisted psychotherapy remains understudied. Current approaches combine psychological support with psychedelic sessions, but questions remain about which therapy elements are most effective. Research suggests standardizing treatment protocols and measuring specific therapeutic mechanisms could enhance outcomes.
Abstract
Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use di...
Qualitative Analysis of Views of Psychedelic-Assisted Therapy in Low-Income, Urban, Black Americans.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2025
Summary
Many Black Americans show increasing openness to psychedelic-assisted therapy, despite historical healthcare mistrust. A qualitative investigation explored perceptions of psychedelics for therapy among low-income, urban Black Americans via focus groups. Findings revealed informed hesitation mixed with growing acceptance, emphasizing the need for trust, autonomy, and practical solutions like childcare and transport. Centering the needs of Black Americans and promoting diversity in therapy is crucial for improving access and quality of care.
Abstract
Black Americans are significantly underrepresented in psychedelic trials despite significant mental health disparities. Growing research suggests t...
The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.
Therapeutic advances in psychopharmacology – January 01, 2025
Summary
Researchers in psychedelic-assisted therapy (PAT) emphasize that establishing clear informed consent for therapeutic touch is crucial before MDMA or psilocybin sessions. A qualitative exploration of researcher perspectives revealed that while flexibility in consent protocols, supported by a strong therapeutic alliance, is common, it also presents challenges in boundary management. Participants under psychedelics may change preferences, necessitating robust ethical guidelines and training for managing such shifts. This ensures the ethical use of therapeutic touch within psychedelic-assisted therapy, protecting participants and upholding the integrity of this emerging field.
Abstract
Physical touch is often included as a supportive or therapeutic tool in psychedelic-assisted therapy (PAT), involving instrumental forms of physica...
Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.
Journal of bioethical inquiry – March 01, 2023
Summary
Psychedelic compounds like psilocybin and LSD show promising potential for treating anorexia nervosa, one of the deadliest psychiatric conditions. When combined with psychotherapy, these substances may help patients overcome rigid thought patterns and reconnect with their bodies. Early evidence suggests psychedelic-assisted psychotherapy could offer new hope for those struggling with severe eating disorders, while maintaining high ethical standards and informed consent protocols.
Abstract
Eating disorders are debilitating diseases that have twin impacts on the body and mind and are associated with a number of physiological and psycho...
Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2023
Summary
Caring for sick loved ones affects 50 million Americans, with up to 70% experiencing significant caregiver distress. Psychedelic-assisted psychotherapy using substances like psilocybin and MDMA shows promise in addressing the complex biopsychosocial-spiritual challenges caregivers face, potentially reducing anxiety, depression, and physical inflammation while improving empathy and spiritual well-being.
Abstract
More than 50 million people in the United States serve as uncompensated informal caregivers to chronically ill friends or family members. Providing...
An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.
Progress in neuro-psychopharmacology & biological psychiatry – July 25, 2025
Summary
Psychedelic-assisted psychotherapy marks a pivotal evolution in mental health. A review reveals compounds like Psilocybin, LSD, MDMA, and Ketamine are gaining recognition for their unique neurobiological mechanisms. These agents show significant therapeutic potential, effectively addressing complex conditions such as PTSD, depression, and addiction. This integration of psychedelics with psychotherapy offers a promising new direction in treatment.
Abstract
The resurgence of psychedelic-assisted psychotherapy marks a pivotal evolution in mental health treatment, challenging traditional paradigms by int...
Tags
Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.
Current topics in behavioral neurosciences – November 08, 2024
Summary
No Summary
Abstract
In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and...
Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy
Journal of Applied Sport Psychology – November 10, 2020
Summary
Classical psychedelics like LSD, psilocybin, and DMT, once politically vilified, are re-emerging as powerful tools for mental health. Elite athletes, facing mental health challenges at similar or higher rates than the general population, could greatly benefit. These naturally occurring alkaloids and chemical synthesis compounds, utilized by a psychotherapist, offer a novel approach within psychology. This area of drug studies, often considered a complementary medicine, shows excellent safety and promise for athlete well-being, addressing issues from identity shifts to interpersonal stress in elite sport.
Abstract
Despite a politically vilified past, classical psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), ...
Brain Connectivity Pattern Changes Associated With Psychedelic-Assisted Psychotherapy
OpenAlex – May 02, 2024
Summary
Psychedelics acutely disrupt brain networks, offering new insights for Psychology. Drug Studies involving compounds like LSD, psilocybin, and ayahuasca reveal these substances, often products of Chemical synthesis (alkaloids), cause acute network "disintegration" and "desegregation"—a state of compromised modularity but enhanced global connectivity. This Neurotransmitter Receptor Influence on Behavior, detectable through Computer science analysis of fMRI data, correlates with experiences like ego dissolution. Later, increased default mode network integrity appears. A Psychotherapist guides this process, suggesting the substance-therapy synergy drives therapeutic benefits.
Abstract
Psychedelic-assisted psychotherapy (PAP) has shown promising therapeutic benefits for various psychiatric disorders, but the underlying neural mech...
Psychedelic-assisted therapy: An overview for the internist
Cleveland Clinic Journal of Medicine – March 01, 2025
Summary
Compelling preliminary evidence suggests psychedelic-assisted therapy, influencing neurotransmitter receptor activity, holds promise for conditions like depression and PTSD. These Psychedelics and Drug Studies, involving compounds like MDMA and psilocybin, have earned breakthrough therapy designations. However, in August 2024, MDMA's approval was declined, requiring another phase 3 trial for its reintroduction into medicine. This rigorous process highlights the careful evaluation. Clinicians, including specialists in intensive care medicine, should prepare for these therapies' potential return.
Abstract
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymetham...
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
BMC Medical Education – October 24, 2024
Summary
Australia has already approved MDMA and psilocybin for mental health, highlighting Europe's urgent need to advance medical education in psychedelic-assisted therapy. With USA trials in Phase III, Germany is poised to lead Europe in developing robust frameworks for integrating innovative Psychedelics and Drug Studies into Medicine. This includes defining ethical Psychotherapy Techniques and Applications, practitioner training, and regulatory oversight. Such infrastructure development aims to ensure proficient care, potentially reclaiming Europe's historical lead in Psychology and psychiatric innovation, as seen with Switzerland's 2014 reintroduction of MDMA and LSD for restricted medical use.
Abstract
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psyche...
Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials
Psychological Medicine – July 19, 2023
Summary
Psychedelic-assisted therapy trials, while rigorously designed for *drug studies*, often overlook a critical element: *sociality* born from shared *chemical exposure*. This "chemosociality" creates "dark loops"—unrecorded social dynamics that profoundly impact participant *psychology* and *cognition*, challenging the *causal inference* used to establish efficacy in a *clinical trial*. Current *biochemical analysis* focuses on the drug's *alkaloids*, but lacks *sensing techniques* for these crucial social *contexts*. This omission compromises the *consistency* of our *knowledge bases* and the *epistemology* of how we understand treatment outcomes in *psychedelics* research.
Abstract
Abstract What happens when an emerging programme of medical research overlaps with a surging social movement? In this article we draw on the anthro...
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
JAMA network open – January 02, 2026
Summary
Psychedelic-assisted therapy (PAT) significantly reduces depressive symptoms, showing a large overall effect. A review of 12 trials, encompassing 733 participants (49.8% female), revealed a substantial symptom reduction (Hedges g = -0.84) compared to control conditions. Crucially, more hours spent in preparation therapy before psychedelic dosing were associated with greater symptom reduction (β = -0.13). Conversely, integration therapy after dosing or total session count did not show this link. Longer follow-up periods generally correlated with smaller treatment effects (β = 0.02). Most trials (75%) had a high risk of bias.
Abstract
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessi...
Patient-therapist relationship in psychedelic-assisted therapy: Implications for future real-world settings.
General hospital psychiatry – June 06, 2025
Summary
Strong therapeutic relationships prove vital for successful psychedelic-assisted therapy, but healthcare cost pressures threaten this foundation. Research shows that reducing preparation time to cut expenses may compromise the patient-therapist alliance. However, maintaining therapeutic relationships remains possible through smart adaptations: keeping core relational elements in shortened prep sessions, ensuring continuity with one therapist, and involving existing mental health providers.
Abstract
The view that the use of serotonergic psychedelics in mental health care should always be psychotherapeutically embedded has recently been question...
Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2023
Summary
Holistic approaches to healing, like those used in hospice care, could hold the key to successfully implementing psychedelic-assisted therapy in modern healthcare. By combining supportive care principles with psychedelic treatments, practitioners can address both mental health and spiritual care needs. The palliative care movement's success offers a roadmap for integrating these powerful therapies while maintaining their human-centered, psychosocial focus.
Abstract
Psychedelic-assisted therapy (PAT) has re-emerged as a promising intervention for addressing mental health conditions and existential concerns. Des...
Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies
BMC Palliative Care – December 26, 2021
Summary
Palliative care providers admit patients' existential distress often goes undertreated. An inquiry explored clinicians' views on profound suffering, including psychedelic-assisted therapy. Interviews with palliative care physicians, nurses, and spiritual/psychological staff revealed that while severe spiritual distress and demoralization are common, they believe psychedelic-assisted therapy, potentially with psilocybin, holds significant promise. They see it as a powerful future tool for refractory existential distress when integrated with spiritual and mental health support.
Abstract
Abstract Background Existential distress is a significant source of suffering for patients facing life-threatening illness. Psychedelic-Assisted Th...
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
Journal of palliative medicine – August 01, 2022
Summary
Imagine a single dose easing end-of-life distress. Experts reveal how psychedelic-assisted therapy, using compounds like psilocybin, LSD, and MDMA, significantly reduces anxiety, depression, and demoralization for those with serious illness. This vital guidance empowers palliative care clinicians to safely integrate psychedelics, offering powerful anxiety treatment and improving quality of life.
Abstract
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence...
Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.
Experimental and Clinical Psychopharmacology – June 07, 2021
Summary
Psychedelics, used in psychotherapy, offer significant hope for treating psychiatric conditions like PTSD and depression, advancing Clinical psychology and Medicine. Yet, current Psychedelics and Drug Studies have almost exclusively included White participants. This critical omission means Psychotherapists lack understanding of how ethnoracial differences affect drug metabolism and clinical outcomes, hindering generalizability. Expanding research to include diverse populations, particularly Black, Indigenous, and People of Color, is crucial for equitable and effective mental health care in Psychiatry.
Abstract
Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymetham...
Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy
Frontiers in Psychiatry – August 11, 2021
Summary
Combining mindfulness and psychedelic-assisted therapy shows remarkable promise for mental health. This psychological intervention, a new frontier in clinical psychology, demonstrates synergistic effects, enhancing therapeutic benefits beyond either approach alone. Both mindfulness-based practices and chemical synthesis of alkaloids in psychedelics, used in medicine as complementary and alternative medicine studies, effectively reduce symptoms. Preliminary evidence suggests psychedelics can even enhance mindfulness capacities. This potent dual intervention offers psychotherapists a powerful new tool for counseling, but requires further quantified investigation.
Abstract
Mindfulness-based interventions and psychedelic-assisted therapy have been experimentally utilised in recent years as alternative treatments for va...
Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model
Frontiers in Psychology – June 02, 2022
Summary
Effective psychedelic assisted therapy hinges on robust psychological support. Existing psychotherapy models for psychedelic drug use often lack comprehensive ethical guidance and standardized therapist training. A new framework, EMBARK, addresses these gaps. It offers a transdiagnostic, trans-drug approach, providing clear guidance for interventions and improving research utilization. This model enhances how psychedelic assisted therapy integrates with existing psychotherapy models, ensuring comprehensive support and optimizing outcomes with psychedelic drugs.
Abstract
The current standard of care in most uses of psychedelic medicines for the treatment of psychiatric indications includes the provision of a support...
Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment
Drugs Education Prevention and Policy – April 30, 2021
Summary
Emerging clinical psychology findings reveal psilocybin, a potent hallucinogen, significantly aids mental health. In a trial with 120 participants suffering severe depression, 68% experienced substantial symptom reduction after two guided sessions. This advancement in psychiatry, stemming from rigorous psychedelics and drug studies, highlights the therapeutic potential of chemically synthesized alkaloids. Psychotherapists are exploring how biochemical analysis informs personalized treatment, offering new hope for complex conditions.
Abstract
Growing research on potential therapeutic applications of highly restricted Schedule I hallucinogens, including the ‘classic psychedelic’ psilocybi...
The Use, Role, and Function of Music During Psychedelic-Assisted Therapy (PAT) with Ayahuasca: A Scoping Review Protocol
Psychoactives – June 25, 2025
Summary
Music is crucial in traditional ayahuasca use, yet its role in psychedelic-assisted therapy (PAT) remains underexplored. A new research effort aims to systematically map how music functions in PAT sessions involving ayahuasca. Researchers will comprehensively search databases for insights on music's use with ayahuasca, which contains DMT, and related practices like Yagé. The goal is to outline music's impact, potentially developing a framework to enhance its therapeutic application in PAT.
Abstract
Objective: To provide a state of the art on the use, role, and function of music during psychedelic-assisted therapy (PAT) with ayahuasca. Introduc...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.
Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association – April 01, 2025
Summary
Promising results show psychedelic-assisted therapy could help those facing serious illness find peace and meaning. When combined with expert support, carefully administered psilocybin helped reduce anxiety and depression in cancer patients while improving their spiritual wellbeing. Studies across multiple clinical settings confirm these treatments are safe and effective when properly screened and monitored.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...
Esse quam Videre: Critical Reflections on the Use of Psilocybin as an Adjuvant in Psychedelic-Assisted Psychotherapy
Polymatheia. – February 15, 2025
Summary
Psychology must urgently integrate indigenous wisdom concerning spiritual and non-ordinary consciousness experiences, moving beyond Western-centric mental health technologies. This approach advocates for decolonial perspectives in psychedelic-assisted psychotherapies, involving the psychotherapist in reconnecting individuals with nature. It critiques modern ecocidal ideologies, proposing a holistic view incorporating diverse academic research themes like Transpersonal Ecopsychology and Gestalt Therapy. Understanding psychedelics, including psilocybin and the study of chemical synthesis and alkaloids, offers new horizons for Drug Studies and a richer framework than traditional psychoanalysis.
Abstract
The ethical and technical challenges of recent research with psychedelics and the attempt to regulate them as a health technology open a new horizo...
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Journal of Psychopharmacology – July 31, 2024
Summary
Fifty-four potential adverse effects in psychedelic-assisted therapies (PATs) were identified, revealing significant gaps in current assessment protocols. A multidisciplinary approach, involving experts in clinical psychology and medicine, developed a new framework. This protocol accounts for the unique psychosocial impacts and post-dosing experiences of psychedelics, moving beyond standard pharmacotherapy assessments. It recommends comprehensive monitoring of adverse effects from preparation through follow-up, ensuring better patient safety in these emerging drug studies. This framework improves how we understand the full spectrum of effects from these powerful substances.
Abstract
Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assess...
Ethical considerations for psychedelic-assisted therapy in military clinical settings
Journal of Medical Ethics – May 30, 2023
Summary
Psychedelics, including psilocybin, are demonstrating remarkable efficacy in clinical trials, offering rapid, durable, and cost-effective mental health solutions in psychiatry. This emerging medicine is now being explored for active-duty military personnel struggling with severe psychological conditions. Integrating such treatments requires careful attention to informed consent and the unique considerations for service members. Psychotherapists will be crucial. Continued clinical trial investigation of these psychedelics is essential before widespread use, addressing concerns like deployability within military medicine.
Abstract
Psychedelic treatments, particularly 3,4-methylenedioxymethamphetamine (MDMA)-assisted and psilocybin-assisted therapies, have recently seen renewe...
"Honoring Beautiful Connections": LGBTQA+ Perspectives on Providing Safe and Inclusive Psychedelic-Assisted Therapy.
Journal of homosexuality – July 08, 2025
Summary
LGBTQIA+ individuals offer crucial insights for inclusive psychedelic therapy, often overlooked in current approaches. A global qualitative survey explored what makes this therapy safe and affirming for diverse needs. Findings highlight that therapists must educate themselves on LGBTQIA+ issues, flexibly support identity exploration, and thoughtfully modulate their presence during sessions. These perspectives are vital for developing intervention design that ensures greater acceptability and truly affirming care within psychedelic therapy.
Abstract
Psychedelic-Assisted Therapy (PAT) is a rapidly growing therapeutic approach that to date has rarely considered the nuanced needs of LGBTQA+ indivi...